Breaking Finance News

A statement released earlier today by BNP PARIBAS about Fresenius (ETR:FRE) bumps the target price to 78.00EUR

Indicating a possible upside of 0.13%, BNP PARIBAS raised the price target of Fresenius (ETR:FRE) to 78EUR.

On 9/15/2016, Warburg Research released a statement on Fresenius(ETR:FRE) bumped the target price from 0.00EUR to 73.40EUR. At the time, this indicated a possible upside of 0.04%.

Just yesterday Fresenius (ETR:FRE) traded 0.00% even at 69.28EUR. FRE’s 50-day moving average is 0.00EUR and its 200-day average is 0.00EUR. With the last close up 0.00% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same time period. 0 shares of FRE traded hands, from ann avg. volume of 0.

Performance Graphic:

Fresenius (ETR:FRE)

Fresenius has a one-year low of 0.00EUR and a one-year high of 0.00EUR. Fresenius’s market cap is presently 0.0 EUR.

About Fresenius (ETR:FRE)

Fresenius SE & Co KGaA is a health care company. It operates in the healthcare sector and offers products and services for dialysis, hospitals and outpatient medical care. It focuses on the hospital operations and offers engineering and services for hospitals and other health care facilities. The Company’s operating segments include Fresenius Medical Care; Fresenius Kabi; Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment provides dialysis care and dialysis products for patients with chronic kidney failure. The Fresenius Kabi segment is engaged in provision of intravenously administered drugs (IV drugs), infusion therapies, and clinical nutrition and outpatient care. The Fresenius Helios segment is a private hospital operator and operates 72 clinics. The Fresenius Vamed segment provides engineering and services for hospitals and other health care facilities internationally.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *